Effectiveness and safety of convalescent anti SARS-CoV-2 plasma in the treatment of the early phase of novel coronavirus infection (COVID-19) in hospitalized risk patients: an interventional randomized clinical study
Más información
Fecha de publicación: | 2020 |
Objetivos: | Currently there is no standard treatment for SARS-CoV-2 infection. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including SARS-CoV-1 , MERS-CoV and Hantavirus infection. This study is an openlabel randomized trial in which patients with high risk of COVID |
Año de Inicio/Término: | 2020-2020 |
Financiamiento/Sponsor: | Fondo de Adopción Tecnológica SiEmpre SOFOFA Hub |
Rol del Usuario: | COINVESTIGADOR(A) |
URL: | https://clinicaltrials.gov/ct2/show/NCT04375098 |
DOI: |
200415015 |